Qantas is no longer a turnaround story. The post Why I would buy Qantas shares in 2026 appeared first on The Motley Fool ...

Main Street Capital (MAIN) offers resilient NAV growth and well-covered 5–7% dividends, but a premium valuation limits upside ...

Nasdaq’s push into tokenized securities points to a shift that could soon hit corporate treasury, writes blockchain executive ...

Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using ...

Trading at approximately $220 per share, Lam Research (LRCX) is close to its 52-week high. Do you consider LRCX stock a sound ...

Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers ...

In its latest outlook on Indian PSU banks, HSBC said the sector is entering a phase of structurally stronger growth following ...